title: Non-alcoholic fatty liver disease in 2016.
abstract: Non-alcoholic fatty liver disease is the commonest cause of liver disease worldwide, and is rapidly becoming the leading indication for liver transplantation.
  
  
  
  Original articles, reviews and meta-analyses, guidelines.
  
  
  
  NAFLD strongly correlates with obesity and insulin resistance; currently, the best management strategy is weight loss and treatment of the metabolic syndrome.
  
  
  
  Recent data suggest that the presence of fibrosis and not non-alcoholic steatohepatitis (NASH) is the predictor of clinical outcome.
  
  
  
  Many phase 2 and 3 trials are underway. Drugs hoped to be effective are obeticholic acid, elafibranor, glucagon-like peptide-1 analogues and CCR2/5 inhibitors.
  
  
  
  Improved understanding of the pathophysiology of NAFLD should help us identify which patients progress to significant liver disease and to develop therapies to target this population.
authors.affiliation: National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit, Centre for Liver Research, University of Birmingham, Birmingham, UK Liver Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2WB, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Townsend
authors.affiliation: National Institute for Health Research (NIHR) Birmingham Liver Biomedical Research Unit, Centre for Liver Research, University of Birmingham, Birmingham, UK Liver Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2WB, UK p.n.newsome@bham.ac.uk.
authors.forename: Philip N
authors.initials: PN
authors.lastname: Newsome
mesh_terms: D006801:Humans; D007333:Insulin Resistance; D016031:Liver Transplantation; D024821:Metabolic Syndrome / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D065626:Non-alcoholic Fatty Liver Disease / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D009765:Obesity / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D012307:Risk Factors; D040242:Risk Reduction Behavior; D015431:Weight Loss
keywords: NASH; assessment; cardiovascular disease; fibrosis; metabolic syndrome; non-alcoholic fatty liver disease; obesity; treatment